By pausing DMARDs, you may be ‘starting the cascade of getting the patient into trouble by interrupting therapy that’s ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

By 2027, healthcare professionals across the European Union are expected to adopt interoperable digital credentials.

From designing the curriculum to recruiting faculty and students, building a medical school from the ground up is a unique ...

A new study lacked significant results, but when combined with additional studies, the prevention of cardiovascular events ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Teamwork and systematic follow-up strategies among interdisciplinary staff can improve patient engagement and appointment ...

Two years after percutaneous coronary intervention, people at risk of a cardiac event had better outcomes with clopidogrel ...

Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...